AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca
ROCKVILLE, Md. and SHANGHAI, Jan. 18, 2026 /PRNewswire/ — AbelZeta Pharma, Inc. (“AbelZeta”), a global clinical-stage biopharmaceutical company focused on…
